

# Sachin Khurana

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9822025/publications.pdf>

Version: 2024-02-01

18  
papers

101  
citations

1478505

6  
h-index

1474206

9  
g-index

19  
all docs

19  
docs citations

19  
times ranked

146  
citing authors

#	ARTICLE	IF	CITATIONS
1	Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India. <i>Current Problems in Cancer</i> , 2020, 44, 100571.	2.0	16
2	Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: A real-world multicentric cohort analysis from India. <i>Current Problems in Cancer</i> , 2020, 44, 100570.	2.0	14
3	Assessment of Brain Metastasis at Diagnosis in Non-Small-Cell Lung Cancer: A Prospective Observational Study From North India. <i>JCO Global Oncology</i> , 2021, 7, 593-601.	1.8	12
4	Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial. <i>Gynecologic Oncology</i> , 2021, 162, 382-388.	1.4	11
5	Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103225.	4.4	10
6	Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis. <i>Indian Journal of Medical Research</i> , 2019, 150, 575.	1.0	9
7	Acute Myocardial Infarction after First Dose of Rituximab Infusion. <i>Turkish Journal of Haematology</i> , 2014, 31, 95-96.	0.5	8
8	Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice. <i>Current Problems in Cancer</i> , 2020, 44, 100550.	2.0	7
9	Immune checkpoint inhibitors in advanced non-small cell lung cancer: A metacentric experience from India. <i>Current Problems in Cancer</i> , 2020, 44, 100549.	2.0	4
10	An Open-Label Randomized Controlled Trial Comparing the Efficacy and Safety of Pemetrexed-Carboplatin versus (Weekly) Paclitaxel-Carboplatin as First-Line Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer. <i>Oncology</i> , 2021, 99, 389-396.	1.9	4
11	Quality of life, vascular endothelial growth factor inhibition, and survival outcomes with combination oral metronomic therapy in platinum refractory epithelial ovarian carcinoma: Results from a randomized study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6048-6048.	1.6	2
12	CONCORDANCE: A real-world evidence study to evaluate the concordance of detecting epidermal growth factor receptor (EGFR) mutation by circulating tumor DNA* versus tissue biopsy in patients with metastatic non-small cell lung cancer. <i>Indian Journal of Cancer</i> , 2022, 59, 11.	0.2	2
13	CONCORDANCE study: An observational, multicenter, prospective study to evaluate concordance of detecting EGFR mutations by circulating tumor-free DNA versus tissues biopsy in NSCLC.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21615-e21615.	1.6	1
14	Platinum based chemotherapy in elderly patients with non-small cell lung carcinoma (NSCLC): Experience from an Indian tertiary cancer center.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20528-e20528.	1.6	0
15	Predictors of chemotherapy resistance & relapse in gestational trophoblastic neoplasia. <i>Indian Journal of Medical Research</i> , 2020, 152, 595-606.	1.0	0
16	The feasibility of weekly paclitaxel in improving performance status(PS) of advanced non-small cell lung cancer (NSCLC) patients with poor performance status: A single-arm phase two trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21155-e21155.	1.6	0
17	Physical and psychological symptom burden in patients newly diagnosed with solid organ cancers in a tertiary care centre in India.. <i>Journal of Clinical Oncology</i> , 2022, 40, e24081-e24081.	1.6	0
18	Olanzapine versus fosaprepitant for prevention of chemotherapy induced nausea and vomiting in patients receiving carboplatin (AUC $\geq 4$ ) containing chemotherapy regimen: A phase 3 randomized, double-blind, placebo-controlled trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS12149-TPS12149.	1.6	0